Assessment of praziquantel medication for children living in areas where schistosomiasis is common in Bahia and Sergipe
- Conditions
- TherapeuticsC01.610.335.865.859
- Registration Number
- RBR-86kcy37
- Lead Sponsor
- Instituto Gonçalo Moniz (IGM) - Fundação Oswaldo Cruz (Fiocruz-BA)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- Not specified
- Target Recruitment
- Not specified
Age between 4 and 6 years (cohort 1) and 3 months to 3 years (cohort 2); presence of at least 1 Schistosoma mansoni egg detected through parasitological methods; minimum body weight of 8 kg for children between 2 and 6 years and 5 kg for children under 2 years
Presence of conditions that contraindicate the use of praziquantel at the discretion of the physician, such as viral or bacterial infections, diarrhea, gastroenteritis, among others; have undergone treatment with praziquantel in the last 6 months; concomitant treatment with other drugs that can affect the metabolism of praziquantel, such as some antiepileptics, glucocorticoids, chloroquine, rifampicin, or cimetidine; participants with hepatosplenic schistosomiasis; participants with body temperature above 37.5°C
Study & Design
- Study Type
- Intervention
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method